The strong beat and reaffirmed overall guidance support a bullish view, but the Cortrophin guidance trim introduces modest uncertainty. Monitor the gout expansion's contribution in Q3 and Q4 to see if the lowered Cortrophin range proves conservative. The stock may trade up on the beat but could face resistance if the guidance adjustment is viewed as a signal of slowing momentum.
Drugs in focus
ANIP drug pipeline →Cortrophin Gel
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available since January 2022.
- Next catalyst
- None dated
What to watchCortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 7 $78.25entry
- T+1 · 3mo ago −3.18%α −3.15% · $75.76
- T+5 · 3mo ago −2.19%α −2.58% · $76.54
- T+20 · 3mo ago −8.97%α −8.57% · $71.23
- T+60 · 20d ago −7.99%α −5.72% · $72.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ANI Pharmaceuticals reported record Q2 2026 revenue of $266.0M (+25.9% YoY), beating consensus of $260.1M. Adjusted non-GAAP diluted EPS of $2.21 beat the $2.04 estimate by 8.2%. Cortrophin Gel revenue surged 43.5% to $117.1M, driven by strong demand across existing specialties and early positive signals from the gout expansion. The company reaffirmed full-year total revenue guidance of $1,080-$1,140M and adjusted EBITDA of $285-$300M, but narrowed Cortrophin Gel guidance to $520-$540M (from $540-$575M), reflecting a modest trim to the top end. Overall, a strong beat with solid execution, though the Cortrophin guidance adjustment may temper enthusiasm.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $266.0M vs consensus $260.1M (beat by 2.3%)
- Adjusted non-GAAP diluted EPS $2.21 vs consensus $2.04 (beat by 8.2%)
- Cortrophin Gel revenue $117.1M, +43.5% YoY
- Adjusted non-GAAP EBITDA $71.6M, +32.4% YoY
- Full-year total revenue guidance reaffirmed at $1,080-$1,140M
- Cortrophin Gel guidance narrowed to $520-$540M (from $540-$575M)
- Gout expansion sales force fully operational; early demand metrics positive
- GAAP diluted EPS $1.05 vs $0.36 in prior year period
- Cash flow from operations $115.0M YTD; cash balance $360.2M
Financial Impact
Revenue beat of ~$5.9M vs consensus; EPS beat of $0.17; Cortrophin guidance trimmed by $20-35M at the top end
Risk Factors
- Cortrophin Gel guidance narrowed, implying slower H2 growth vs prior expectations
- ILUVIEN revenue declined 16.1% YoY due to timing of international shipments
- Gross margin compression (GAAP 62.4% vs 64.7% prior year) from royalty-bearing product mix
- Execution risk on gout expansion and new product launches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000068 |
| Document: anicorporatepresentation.htm | 0001023024-26-000068 |
| Document: ani-20260807.htm | 0001023024-26-000068 |
| Document: 0001023024-26-000068-index-headers.html | 0001023024-26-000068 |
| Document: 0001023024-26-000068-index.html | 0001023024-26-000068 |
| Document: 0001023024-26-000068.txt | 0001023024-26-000068 |
| 8-K Data (Synthetic) | 0001023024-26-000068 |
Track record
34 reports on ANIP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers